Vertex Pharmaceuticals (VRTX) Current Leases (2012 - 2018)

Vertex Pharmaceuticals' Current Leases history runs 7 years deep, the most recent figure standing at $9.8 million for Q4 2018.

• On a quarterly basis, Current Leases fell 56.43% year-over-year to $9.8 million in Q4 2018; TTM through Dec 2018 was $9.8 million, a 56.43% decrease from a year earlier, with the FY2018 full-year figure at $9.8 million, down 56.43% from the prior year.
• Current Leases eased to $9.8 million in Q4 2018 per VRTX's latest filing, from $11.5 million in the prior quarter.
• Across five years, Current Leases topped out at $22.5 million in Q4 2017 and bottomed at $9.8 million in Q4 2018.
• The 5-year median for Current Leases is $17.8 million (2014), against an average of $17.1 million.
• Across the five-year window, Current Leases jumped 120.71% in 2014 and plunged 56.43% in 2018, its largest moves.
• Year by year, Current Leases stood at $17.8 million in 2014, then decreased by 12.7% to $15.5 million in 2015, then rose by 24.97% to $19.4 million in 2016, then grew by 15.98% to $22.5 million in 2017, then plunged by 56.43% to $9.8 million in 2018.
• Per Business Quant, the three latest VRTX Current Leases figures stand at $9.8 million (Q4 2018), $11.5 million (Q3 2018), and $15.1 million (Q2 2018).